| Efficacy and safety of sequential treatment with parenteral sulbactam/ampicillin and oral sultamicillin for skeletal infections in children. | |
| | |
MedLine Citation:
|
PMID: 3026018 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Nine children with osteomyelitis and/or septic arthritis were treated sequentially with parenteral sulbactam/ampicillin and oral sultamicillin. Causative pathogens were identified in six cases; all were susceptible to the combination of ampicillin and sulbactam. The mean duration of parenteral therapy was 7.1 days (6-11 days), and the average hospital stay was 10.3 days (6-18 days). Peak serum bactericidal titers of greater than or equal to 1:8 were achieved in all patients during parenteral therapy; only one child receiving oral therapy did not achieve a titer of greater than or equal to 1:4. At follow-up, all of the children were cured clinically and there was no evidence of relapse. Adverse reactions to oral therapy were minimal. The regimen of parenteral sulbactam/ampicillin and oral sultamicillin used sequentially is effective and safe for the treatment of skeletal infections in children. The use of this approach significantly reduced the duration of hospitalization. |
| | |
Authors:
|
S C Aronoff; P V Scoles; J T Makley; M R Jacobs; J L Blumer; A Kalamchi |
Related Documents
:
|
21697818 - Dietary factors and their associations with socioeconomic background in finnish girls a... 6427608 - Treatment of episodic hyperammonemia in children with inborn errors of urea synthesis. 9744178 - Compliance with anti-tuberculosis preventive therapy among 6-year-old children. 22494638 - Repair of near-atretic coarctation of the aorta in children with a new low-profile cove... 12214368 - Exposure-based death rates for child motor vehicle occupants. 12632788 - Clinical evaluation of short children referred by school screening: an analysis of 655 ... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Reviews of infectious diseases Volume: 8 Suppl 5 ISSN: 0162-0886 ISO Abbreviation: Rev. Infect. Dis. Publication Date: 1986 Nov-Dec |
Date Detail:
|
Created Date: 1987-02-06 Completed Date: 1987-02-06 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 7905878 Medline TA: Rev Infect Dis Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: S639-43 Citation Subset: IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Oral Adolescent Ampicillin / administration & dosage, adverse effects, therapeutic use* Arthritis, Infectious / drug therapy* Bacterial Infections / drug therapy Child Drug Combinations / administration & dosage, adverse effects, therapeutic use Female Haemophilus Infections / drug therapy Haemophilus influenzae / drug effects Humans Infant Infusions, Parenteral Male Osteomyelitis / drug therapy* Penicillanic Acid / administration & dosage, adverse effects, therapeutic use* Prospective Studies Staphylococcal Infections / drug therapy Staphylococcus aureus / drug effects Sulbactam |
| Chemical | |
Reg. No./Substance:
|
0/Drug Combinations; 68373-14-8/Sulbactam; 69-53-4/Ampicillin; 76497-13-7/sultamicillin; 87-53-6/Penicillanic Acid |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A randomized comparative study of sulbactam plus ampicillin vs. metronidazole plus cefotaxime in the...
Next Document: Sulbactam plus ampicillin: interim review of efficacy and safety for therapeutic and prophylactic us...